GLENMARK PHARMACEUTICALS

BSE: 532296 30 Sep 2025

Healthcare

₹ 1944.8

Glenmark Pharmaceuticals ltd specializes in Pharmaceuticals within the Healthcare sector.

GLENMARK PHARMACEUTICALS

BSE: 532296 30 Sep 2025

Healthcare

₹ 1944.8

Glenmark Pharmaceuticals ltd specializes in Pharmaceuticals within the Healthcare sector.

Book Value

314.0

Dividend Yield

0.13%

Debt to Equity

0.28

Stock P/E

41.8

Market Cap

55,642 Cr

GLENMARK PHARMACEUTICALS - Share Price & Details

Market Cap

₹55,642

High /Low

2,286 / 1,275

Stock P/E

41.8

Book Value

₹314.0

Dividend Yield

0.13

ROCE

19.4

ROE

₹15.8

Face Value

1.0

PEG Ratio

6.68

EVEBITDA

₹23.0

Debt

2,473

CMP / FCF

-62.7

Debt to equity

₹0.28

NP Ann

1,047

High price all time

2,286

Piotroski score

₹6.0

Graham Number

434.0

No. Eq. Shares

28.2

Net CF

₹17.4

Net profit

754

Price to book value

6.29

Interest Coverage

₹8.66

Low price all time

109.0

Industry PE

33.0

Reserves

₹8,821

Free Cash Flow

₹-1,575

Broker Recommendations

Date	Author	Type	Reco Price	Target Price	Potential	Source	PDF Link
19 Aug 2025	ICICI Securities	Sell	₹1,945.9	₹1,570	-18.3%	moneycontrol	View
18 Aug 2025	Motilal Oswal	Buy	₹1,974.4	₹2,400	23.6%	moneycontrol	View
18 Jul 2025	ICICI Securities	Sell	₹2,226.65	₹1,620	-27.2%	moneycontrol	View
11 Jul 2025	Motilal Oswal	Buy	₹1,905.15	₹2,430	11.4%	moneycontrol	View
26 May 2025	Motilal Oswal	Buy	₹1,389.2	₹1,690	22.4%	moneycontrol	View
18 Feb 2025	KRChoksey	Buy	₹1,377.65	₹1,768	28.1%	moneycontrol	View
20 Aug 2024	KRChoksey	Buy	₹1,637.65	₹1,894	20.9%	moneycontrol	View
16 Aug 2024	Motilal Oswal	Buy	₹1,564.7	₹1,850	18.1%	moneycontrol	View
03 Jun 2024	KRChoksey	Buy	₹1,175.4	₹1,403	-10%	moneycontrol	View
27 May 2024	Motilal Oswal	Hold	₹1,120.3	₹1,050	-32.6%	moneycontrol	View
05 Apr 2024	KRChoksey	Buy	₹1,017	₹1,266	-18.8%	moneycontrol	View
22 Feb 2024	KRChoksey	Buy	₹913.3	₹984	-36.8%	moneycontrol	View

Price Chart

Volume Chart

Peer Comparison

Stock	Total Income	Net Profit	Net Sales	EPS	Market Cap (in Cr)	P/E
FABINO ENTERPRISES LIMITED	NA	NA	NA	NA	5.09	84.8
Triochem Products Ltd.,	NA	NA	NA	NA	0
GLENMARK PHARMACEUTICALS LTD.	24642.63	3302.26	23949.28	11.7	55,642	41.8
BIOCON LTD.	5984.0	-83.0	5371.0	-0.07	45310	125.0
GLAXOSMITHKLINE PHARMACEUTICAL	8485.9	2047.0	8048.3	12.08	45272	47.8

Peer Comparison Chart

About GLENMARK PHARMACEUTICALS

Glenmark Pharmaceuticals ltd, with Security Code 532296, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.

Order Book

Latest News

Stocks to Watch Today Tuesday 23 September: Maruti Suzuki, NTPC, Glenmark Pharmaceuticals, Brigade Enterprises, and more

(23 Sep 2025)

Stocks to watch on September 23 include Maruti Suzuki, NTPC, Glenmark, Brigade Enterprises, and others, as corporate actions, festive demand...

Glenmark Pharma board to consider interim dividend on September 26

(22 Sep 2025)

The record date for payment of the interim dividend has been fixed as Tuesday, September 30. Shares of Glenmark Pharmaceuticals Ltd ended at...

Stocks to Watch: KFin Technologies, Brigade Enterprises, RVNL and more

(22 Sep 2025)

Here are a few stocks to watch for tomorrow: Glenmark Pharma ahead of its board meet on interim dividend, Brigade Enterprises with a ₹1200...

Here's Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Is The Least Of Shareholders' Concerns

(20 Sep 2025)

Key Insights Glenmark Pharmaceuticals to hold its Annual General Meeting on 26th of September Salary of ₹149.9m is part...

Glenmark Pharma shares rise 2.08% on price increase

(19 Sep 2025)

Glenmark Pharma shares gained 2.08% to trade at Rs 2,084.80 at 10:45 am. This increase reflects a positive movement in the stock's price...

CRISIL raises Glenmark Pharma's outlook to 'Positive', reaffirms ratings

(19 Sep 2025)

CRISIL Ratings has revised the outlook on the long-term bank facilities of Glenmark Pharmaceuticals Limited (Glenmark) to `Positive' from...

Quarterly Table

Standalone Consolidated

Metrics	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Sales	1,939.0	2,144.4	2,233.4	1,365.1	2,148.2	2,329.5	2,636.1	2,251.3	2,009.5	2,394.9
Expenses	1,721.4	1,659.4	1,789.9	1,549.4	1,650.8	1,698.4	1,857.5	1,757.4	1,668.9	1,666.8
Operating Profit	217.7	485.0	443.5	-184.3	497.4	631.1	778.6	493.9	340.5	728.2
OPM %	11.23%	22.62%	19.86%	-13.5%	23.16%	27.09%	29.54%	21.94%	16.95%	30.4%
Other Income	-425.4	17.7	53.9	233.5	5,933.2	55.6	83.1	129.2	-90.7	-253.9
Interest	58.9	61.9	58.2	73.6	83.4	15.3	11.8	8.5	13.1	15.5
Depreciation	46.7	48.8	49.8	51.2	52.4	53.1	54.8	55.2	55.5	57.6
Profit before tax	345.0	423.7	409.0	-50.2	1,147.9	618.3	795.1	559.5	360.3	724.4
Tax %	-56.1%	-30.7%	-22.3%	-73%	-26.7%	-26.6%	-25.2%	-26%	-18.4%	17.7%
Net Profit	-137.5	271.7	302.4	-20.4	4,613.7	453.7	595.1	413.8	147.8	330.2
EPS in Rs	-4.87	9.63	10.72	-0.72	163.5	16.08	21.09	14.66	0	11.7

Metrics	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	3,463.9	3,373.7	3,401.6	3,207.4	2,506.7	3,063.0	3,244.2	3,433.8	3,387.6	3,256.2
Expenses	2,843.6	2,768.7	2,770.4	2,745.1	2,715.4	2,558.6	2,656.0	2,831.9	2,787.3	2,695.1
Operating Profit	620.2	605.0	631.2	462.3	-208.6	504.3	588.2	601.9	600.2	561.1
OPM %	17.91%	17.93%	18.56%	14.41%	-8.32%	16.47%	18.13%	17.53%	17.72%	17.23%
Other Income	110.3	-839.9	-31.2	-323.7	-31.3	326.4	31.5	39.4	31.1	-361.1
Interest	97.3	109.3	112.0	121.5	134.3	148.6	39.6	48.5	52.3	66.7
Depreciation	162.3	146.5	154.7	141.5	147.1	151.3	117.8	120.3	122.7	125.2
Profit before tax	437.1	309.0	385.4	201.1	-444.7	977.6	462.3	472.6	456.3	380.9
Tax %	-38.3%	-17.9%	-48.1%	45%	-13.8%	-333.3%	26.4%	25%	23.7%	-43.9%
Net Profit	290.8	-403.1	173.1	-63.6	-330.8	-1,214.3	340.2	354.5	348.0	4.4
EPS in Rs	9.66	-15.18	5.31	-2.9	-12.45	-43.18	12.06	12.55	12.33	0

Shareholding Distribution

Shareholding Pattern

Compounded Data

Consolidated

Standalone

Compounded Sales Growth
10 Years:	13%
5 Years:	5%
3 Years:	1%
TTM:	22%

Compounded Profit Growth
10 Years:	13%
5 Years:	1%
3 Years:	-4%
TTM:	119%

Stock Price CAGR
10 Years:	5%
5 Years:	32%
3 Years:	54%
1 Year:	39%

Compounded Sales Growth
10 Years:	7%
5 Years:	4%
3 Years:	3%
TTM:	12%

Compounded Profit Growth
10 Years:	0%
5 Years:	0%
3 Years:	0%
TTM:	-5102%

Stock Price CAGR
10 Years:	5%
5 Years:	32%
3 Years:	54%
1 Year:	39%

All Deals

Date	Stock	Party	Deal	Acq. Mode	Trans.	Quan.	Price	Value

Stock Mutual Funds Data

Order Book

News Date ▲▼	Headline ▲▼	Issuer Entity ▲▼	Issuer Type ▲▼	Order Size ▲▼	Time Period ▲▼
Loading company updates…

Loading technicals…

Moving Averages

Latest Close: — • Records Used: — • Last Trading Date: —

Simple Moving Averages (SMA)

Period	SMA Value	Status

Exponential Moving Averages (EMA)

Period	EMA Value	Status

Oscillators

Key Oscillators

latest calculation

Indicator	Value

GLENMARK PHARMACEUTICALS

GLENMARK PHARMACEUTICALS

GLENMARK PHARMACEUTICALS - Share Price & Details

Broker Recommendations

Price Chart

Volume Chart

Peer Comparison

Peer Comparison Chart

About GLENMARK PHARMACEUTICALS

Order Book

Latest News

Stocks to Watch Today Tuesday 23 September: Maruti Suzuki, NTPC, Glenmark Pharmaceuticals, Brigade Enterprises, and more

Glenmark Pharma board to consider interim dividend on September 26

Stocks to Watch: KFin Technologies, Brigade Enterprises, RVNL and more

Here's Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Is The Least Of Shareholders' Concerns

Glenmark Pharma shares rise 2.08% on price increase

CRISIL raises Glenmark Pharma's outlook to 'Positive', reaffirms ratings

Glenmark Pharma to transfer its consumer care biz to Glenmark Consumer Care

Glenmark, Indraprastha Gas among 7 key companies to trade Ex-dividend today, 15 September 2025

Glenmark shares fall 1.81%; stock among top losers on Nifty Midcap 150

Dividend Stocks To Watch This Week — Glenmark Pharma, Dixon Tech, Hindustan Copper And More

Dividend stocks: NSDL, Glenmark Pharma, Dixon Tech, Mazagon Dock, SJVN, and others to trade ex-dividend this week

Glenmark Pharma shares rise as arm receives an upfront payment of $700 mn

Glenmark Pharma Share Price Rises as Subsidiary Bags $700 Million Licensing Deal with AbbVie

Glenmark Pharma shares rise 3% as arm receives $700 mn, more details

Glenmark begins phase 3 trial of novel lung cancer drug Envafolimab

Glenmark Pharmaceuticals Inc., USA to launch Eribulin Mesylate Injection, 1mg/2Ml (0.5 mg/mL) Single-Dose Vials

Glenmark’s Workforce Strategy: 14,989 employees, 4.9 lakh training hours, 33% women on Board

Five Stocks To Buy Today: Glenmark Pharma, Bharti Airtel, Others—Check Target Price

Glenmark, Alembic Pharma, Sun Pharma recall products in US: USFDA

Glenmark Pharma shares fall 4% as Q1 earnings show fails to impress

Glenmark Pharma Q1 Net Profit Falls 86% YoY to ₹47 Crore

Buy Glenmark Pharma; target of Rs 2400: Motilal Oswal

Glenmark Pharma falls 5% in 2 days on Q1 show; Here's what analysts suggest

Glenmark Pharma Eyes 19-20% Ebitda Margin In FY26 Driven By Strong Performance Across Markets

Glenmark Pharma share price down 5% in 2 days; 'Sell' stock, says ICICI Securities

Glenmark Pharmaceuticals USA to launch Micafungin for injection USP, 50 mg/vial and 100 mg/vial

Glenmark Pharmaceuticals to launch Micafungin for Injection USP in the United States

Glenmark, Alembic Pharma, Sun Pharma shares slip up to 1.5% on product recalls after USFDA action

Glenmark Pharma USA to Launch Micafungin Injection

Glenmark Pharma Q1 Results | Net profit plunges 86% to ₹47 crore despite stable revenue

Glenmark Pharma Q1 results: Profit falls 86% to ₹47 cr, revenue down 5%

CDSCO Panel Accepts Glenmark's Apremilast Trial Report, Seeks 2-Year PSUR Data

Glenmark Pharma share price falls 2.1% in today's session; stock among top losers on Nifty Midcap 150

Glenmark Pharma Shares Gain as Arm Reaches Settlement in US Antitrust Suit

Glenmark Pharmaceuticals' USA arm reaches $37.75 million settlement in US antitrust lawsuit

Glenmark Pharma share price hits 10% upper circuit on unit's cancer licensing deal with AbbVie | Stock Market News

Glenmark Pharmaceuticals Ltd spurts 1.22%, up for third straight session

Glenmark Pharmaceuticals Limited (532296) Stock Experiences Sudden Dip - Remarkable growth

Glenmark, Laurus: 4 pharma stocks gain up to 79% in 5 months; time to exit?

Glenmark Pharmaceuticals Limited (GLENMARK) to Launch New Product Line - Tremendous growth potential

Technical Analysis: Glenmark Pharmaceuticals Limited (532296) - Market-beating returns

Glenmark Pharma's North Carolina facility gets 5 USFDA observations; no data integrity issues

Glenmark Pharma will turn cash positive with AbbVie's licensing deal: S&P

Glenmark Pharma hits 10% upper circuit, scales fresh 52-week high on $700 mn cancer drug deal

India's Glenmark Pharma soars 10% to record high on AbbVie cancer treatment licensing deal

Glenmark Pharma Stock Soars 10%: Deal with AbbVie Pushes Shares to 52-Week High

Glenmark Pharma shares surge after its U.S arm, AbbVie ink pact for investigational cancer drug

Glenmark Pharma share price hits 10% upper circuit on unit's cancer licensing deal with AbbVie

Glenmark Pharma shares cool off after hitting 20% upper circuit post mega ISB 2001 deal

Glenmark Pharmaceuticals Sees Surge in Open Interest Amid Increased Trading Activity

Glenmark Launches a Transformative Nutrition and Livelihood Project in Emali, Kenya

10 Stocks To Buy For Short Term: Analysts suggest buying largecap, midcap scrips for 2 weeks; Glenmark Pharma, LIC, HPCL on the list

Glenmark Pharmaceuticals shares up 3% on launching cancer drug Tevimbra

Glenmark Pharma launches lung cancer treatment drug in India; shares up 2%

Glenmark Pharma rolls out TEVIMBRA for cancer care in India

Why Hindalco, Timex Group, Manappuram, Glenmark Pharma, Aurobindo Pharma, Keynes Tech, Indo Rama Synthetics, Gravitas, CIE Automotive stocks will remain in focus on June 25

Glenmark Launches TEVIMBRA® in India, Marking Entry into Immuno-Oncology Space

Glenmark Pharma's Monroe facility in North America gets five USFDA observations

Buy Glenmark Pharma, Max Healthcare & Valor Estate shares, suggests Axis Securities

Glenmark Pharmaceuticals Ltd soars 0.98%, rises for fifth straight session

Glenmark Pharmaceuticals to launch DCGI-approved BRUKINSA in India for treatment of hematological malignancies

Glenmark Pharma announces India launch of blood cancer treatment Brukinsa

Glenmark Pharma To Launch Cancer Treatment Drug Zanubrutinib After DGCA Approval

Stocks in Focus: Tata Power, Glenmark Pharma, and Others

Has Glenmark Pharma declared dividend?

Stocks to buy: Rajesh Palviya of Axis Sec suggests Birlasoft, Glenmark Pharma, Heritage Foods shares today - 6 June 2025

I-Sec maintains Reduce call on Glenmark Pharma, raises target price to Rs 1,300

Buy Glenmark Pharma; target of Rs 1690: Motilal Oswal

Licensing deal for cancer drug candidate ISB 2001, shortly: Glenmark CMD